News

The latest news and views from bridge therapeutics
20th July 2018

In this article by PBS explains how traditional opioids interact with the receptors in the brain to produce analgesia (pain relief), constipation, depression, and euphoria. Cathy Cahill PhD, a pain researcher at UCLA also explains how those with chronic pain taking traditional opioids experience big swings of emotion due to the euphoria and subsequent dysphoria…

19th July 2018

America’s opioid epidemic is exacting a massive human toll that also is impacting the economy, Federal Reserve Chairman Jerome Powell said Tuesday. “From an economic standpoint, some high percentage of prime-age people who are not in the labor force, particularly prime-age males who are not in the labor force, are taking painkillers of some kind,”…

19th July 2018

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they will be introducing their chronic pain development program at the American Chronic Pain Association (ACPA) Roundtable. The ACPA offers peer support and education in pain management skills to people with chronic pain, along with their families, friends, and healthcare professionals. Alton Kelley, Director…

10th July 2018

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they would showcase their chronic pain drug development program to venture capitalists at the 2018 Young Startup Ventures Summit in New York. More than 150 venture capitalists will hear pitches and programs from various companies and startups in fields ranging from fintech to life…

27th June 2018

The National Institutes of Health (NIH) recently announced a new set of research priorities around addiction and pain research in efforts to combat the nation’s opioid crisis. The HEAL (Helping to End Addiction Long-term) Initiative was launched by the NIH with support from the president and the Department of Health and Human Services. Under this…

13th June 2018

Bridge Builds Connections at World’s Largest Business Partnering Event. The Bridge Therapeutics Team traveled to Boston for the BIO International Convention. Bridge met with investors as well as worked to attain other sources of capital. The team, also, met with vendors and service providers in preparation for the launch of their lead investigational drug BT-205….

16th May 2018

Bridge Therapeutics has announced they will be expanding their operations into one of the finest locations in Birmingham, Alabama. The new headquarters at the Summit in Birmingham is currently under design by the award-winning architectural firm Chambless King Architects. “Our new headquarters will bring a new energy to Bridge Therapeutics,” said Alton Kelley, Director of Business Development….

16th April 2018

Aiming for an “overall reduction in opioid overuse and overdoses,” Medicare announces starting next year there will be new limits for high-dose opioid prescriptions. The Medicare announcement—part of the 2019 Medicare Advantage and Part D Rate Announcement and Call Letter— sets limits for opioid-naive patients on seven-day prescriptions, and notes the expansion and combination of the…

14th March 2018

The innovative late development-stage pharmaceutical startup, Bridge Therapeutics has announced Tim Peara will be joining its management team as the new Director of Finance, effective immediately. Tim Peara has more than 30 years of experience with institutional investments and technology start-ups. He has negotiated and structured investments, conducted due diligence, and built financial models for…

27th February 2018

Greg Sullivan, MD, Chief Scientific Officer and CEO of Bridge Therapeutics, was recently interviewed by Bronwyn Mixter of Bloomberg BNA about the abuse of gabapentinoid pain drugs. Dr. Sullivan explains how buprenorphine is a safe alternative for many of the dangerous drugs that are currently prescribed for chronic pain. In the article Dr. Sullivan discusses…